Bicycle Therapeutics PLC (BCYC) — 10-Q Filings

10-Q Filings (6)

• Bicycle Therapeutics' Losses Widen on Soaring R&D Costs — Oct 30, 2025 Risk: high
  Bicycle Therapeutics plc reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $198.8 million, up from $117.2 milli
• Bicycle Therapeutics' Q2 Loss Widens Amid R&D Spend — Aug 8, 2025 Risk: high
  Bicycle Therapeutics PLC reported a net loss of $44.6 million for the three months ended June 30, 2025, a significant increase from the $33.2 million net loss i
• Bicycle Therapeutics Q1 2025: Revenue Up, Net Loss Continues — May 1, 2025 Risk: medium
  Bicycle Therapeutics plc filed a 10-Q for the period ending March 31, 2025. The company reported total assets of $690.6 million and total liabilities of $69.2 m
• Bicycle Therapeutics Files Q3 2024 10-Q — Oct 31, 2024 Risk: medium
  Bicycle Therapeutics plc filed a 10-Q for the period ending September 30, 2024. The company, based in Cambridge, UK, is in the pharmaceutical preparations indus
• Bicycle Therapeutics Q2 2024 Update — Aug 6, 2024 Risk: medium
  Bicycle Therapeutics plc filed a 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities, including
• Bicycle Therapeutics plc Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: low
  BICYCLE THERAPEUTICS plc (BCYC) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Bicycle Therapeutics plc filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX